Research Daily Summary: What Happened on October 6, 2026

AstraZeneca opens Cambridge research center

AstraZeneca opened an 18-story, 570,000-square-foot research and development center in Kendall Square, Cambridge, Massachusetts.1 Ten floors hold connected laboratories equipped with automation, robotics, and agentic AI.1

Research at the center will cover breast cancer, chronic obstructive pulmonary disease, metabolic disease, obesity, other cancers, and rare conditions, alongside biologics and cell therapy.1 Together with a nearby genomic medicine site, the campus is expected to accommodate about 2,000 researchers and scientists.1

AstraZeneca said the expansion will lift its Massachusetts workforce by more than 50% over the coming years.1 The Cambridge center is part of the company’s broader $50 billion US investment program.1

Genetic screening finds new metabolic pathways in mammalian cells

Researchers developed shotgun genetic engineering, a method that tests many genetic-component combinations in parallel and can screen millions in one experiment.34 They used it to identify pathways that let mammalian cells grow without certain essential amino acids.24

In Chinese hamster ovary cells, one pathway supported growth without valine at a rate close to unmodified cells, while a six-gene pathway enabled growth without isoleucine.4 The team also enabled valine-independent growth in Jurkat cells.4

The method delivers barcoded genetic components into cells, then uses selection to find combinations that work.34 The authors said the resulting data could train machine-learning models to predict pathway function.4

MOF-Vac vaccine shrinks tumors in mouse studies

An experimental vaccine called MOF-Vac produced tumor regression in mouse models of five cancers, including melanoma, colorectal cancer, and triple-negative breast cancer.5 The vaccine carries peptide antigens and STING agonists together, releasing them inside cells in response to phosphate.5

In the reported studies, MOF-Vac combined with radiotherapy or immune checkpoint blockade eliminated tumors at primary and distant sites.5 Analyses indicated that macrophages presenting antigens and shifting the tumor environment toward an inflammatory, immune-active state drove most of the effect.5

The authors describe the platform as a possible basis for ready-made or personalized cancer vaccines.5

Also published

• Dog brains track speech in a way we thought was unique to humans BioTechniques
• EMBL in Poland: connecting communities, advancing discovery EMBL
• Architect of polar neutrino detector wins physics Nobel Science News
• Realignment of representational drift in mouse visual cortex via flexible electrode arrays Nature Biomedical Engineering
• Fibre-architected intelligent permeable bioelectronics Nature Reviews Bioengineering